Biogen will stop selling its Alzheimer’s drug, Aduhelm, amid controversy. The Biden Administration makes its initial offers to drug companies on the first ten drugs to be negotiated through Medicare, as courts weigh lawsuits brought by pharmaceutical companies challenging the negotiation process. And, participation in Medicare accountable care organizations is up. That’s coming up on today’s episode of Gist Healthcare Daily.
Hosted on Acast. See acast.com/privacy for more information.
